Connect your AI client via MCP

Endpoint (paste into an MCP client — anonymous, free, no key)

https://mcp.koalcheck.com/mcp

Or copy this and send it to your AI to set it up:

Add the "koalcheck" MCP server to my client and connect. It is a remote Streamable-HTTP server at https://mcp.koalcheck.com/mcp — connect anonymously, no API key or login needed (the free tools work right away). If my client supports a remote/HTTP MCP server directly, just use that URL. If my client config only accepts a local command (e.g. Claude Desktop's mcpServers, which rejects a bare "url"), bridge it with command "npx" and args ["-y","mcp-remote","https://mcp.koalcheck.com/mcp"]. Then tell me to fully restart the client, and list the koalcheck tools you can call. It provides US-equity research tools built on an analyst track-record engine (who has actually been right, priced vs SPY, cross-checked with SEC & FINRA).

Capabilities User guide

← @pk_fund

$SLS

BULLISH2026-07-21

Price around the call

↑ 2026-07-21

By horizonMaturing · ~18 trading days to go

✓ +3.4%

…

21d

…

Original post

PK_Fund · 2026-07-21

$SLS The crazy thing is that SLS009 *on its own* at $12.50 is still one of the better buys in biotech right now. Comparable drugs have been snatched up earlier in development for $2B, $3B, even $5B+. SLS009 has already proven its safety profile and effectiveness, and is now just waiting for P2 data to come in and back that data up (in an even healthier population) during Q4 before it’s up for accelerated approval via the FDA. It appears the market has been so busy litigating the success of GPS/REGAL that it missed SLS009 altogether. When you see people linking some other random bio stock they are trying to pump, keep in mind that you, right now, have a play that’s at least as good and it’s already a part of your portfolio, quietly waiting until later this year.

View on X ↗